<DOC>
	<DOC>NCT03005288</DOC>
	<brief_summary>This study will assess the safety, pharmacokinetics and efficacy of bimagrumab when administered in obese patients with type 2 diabetes</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Efficacy of Bimagrumab in Obese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Antibodies, Blocking</mesh_term>
	<criteria>Type 2 diabetes with HbA1c between 7% and 10% at screening with stable treatment for 3 months prior to randomization Body Mass Index of 28 to 40 kg/m2 at screening Body weight between 65 and 140 kg at screening Women of childbearing potential unless they are using highly effective methods of contraception Diabetes other than Type 2 such as Type 1 diabetes, surgically induced diabetes, "brittle" type 2 diabetes as per investigator judgement, history of severe hypoglycemic episodes in the year preceding screening or hypoglycemic unawareness history of clinically significant arrythmias, unstable angina, myocardial infarction or stroke, coronary artery bypass graft surgery, or percutaneous coronary intervention within 6 months of screening or 1 year for drugeluting stents use of antiobesity medications, nutritional supplements or over the counter products ofr weight loss within 3 months of screening use of medications known to induce weight gain such as some anticonvulsant and psychotropic medications within 3 months of screening Any chronic active infection (e.g., HIV, Hepatitis B or C, tuberculosis, etc). uncontrolled thyroid disease. Stable euthyroid patients on stable thyroid replacement therapy for at least 3 months of screening are allowed. Known history or presence of severe active acute or chronic liver disease (e.g., cirrhosis) Uncontrolled depression Use of skeletal muscle anabolic agents in any form for 3 months prior to screening Chronic kidney disease [estimated glomerular filtration rate (GFR) &lt; 30 mL/min];</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>obesity</keyword>
	<keyword>DXA</keyword>
	<keyword>MRI</keyword>
</DOC>